• By ICR Secretariat
  • Posted Thursday, August 11, 2022

FDA approves AstraZeneca, Daiichi drug in breast cancer first

https://www.biopharmadive.com/news/enhertu-her2-low-breast-cancer-fda-approval-astrazeneca/629003/

A new targeted treatment for breast cancer could reshape how doctors classify and treat the disease, offering another option for people whose tumors have spread or are unable to be removed through surgery.